Altimmune, Inc. (NASDAQ:ALT) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. trimmed its stake in shares of Altimmune, Inc. (NASDAQ:ALT) by 11.1% during the fourth quarter, Holdings Channel reports. The firm owned 4,431,612 shares of the company’s stock after selling 552,246 shares during the period. Vanguard Group Inc. owned about 0.06% of Altimmune worth $31,952,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in ALT. SBI Securities Co. Ltd. bought a new position in Altimmune during the 4th quarter worth $45,000. Cullen Frost Bankers Inc. acquired a new position in shares of Altimmune during the fourth quarter valued at $72,000. 180 Wealth Advisors LLC bought a new position in shares of Altimmune during the fourth quarter worth about $78,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Altimmune in the 4th quarter worth about $81,000. Finally, Raymond James Financial Inc. bought a new stake in Altimmune in the 4th quarter valued at about $88,000. Institutional investors own 78.05% of the company’s stock.

Analyst Ratings Changes

Several research analysts have commented on ALT shares. William Blair restated a “market perform” rating on shares of Altimmune in a research report on Friday, March 14th. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, April 3rd. Finally, Stifel Nicolaus initiated coverage on Altimmune in a research report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Trading Up 6.0 %

Shares of NASDAQ:ALT opened at $4.41 on Monday. The company has a 50 day moving average of $5.62 and a 200-day moving average of $6.80. The firm has a market cap of $339.63 million, a P/E ratio of -2.85 and a beta of 0.91. Altimmune, Inc. has a twelve month low of $3.55 and a twelve month high of $11.16.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Equities research analysts forecast that Altimmune, Inc. will post -1.35 EPS for the current year.

Insider Activity

In other Altimmune news, CFO Gregory L. Weaver purchased 10,000 shares of the company’s stock in a transaction on Thursday, March 13th. The shares were purchased at an average cost of $5.20 per share, for a total transaction of $52,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares in the company, valued at $52,000. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.10% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.